SYDNEY, May 14, 2026 /PRNewswire/ -- Leading Australian cancer care provider, GenesisCare, is pleased to be collaborating with SeeTreat to enable suitable cancer patients access to the latest technology in offline adaptive treatment assessment. SeeTreat's ART.1 software will be rolled out at GenesisCare from July 2026 to support automated, adaptive treatment evaluation for eligible patients.

GenesisCare Chief Medical Officer, Dr Marcus Dreosti, explains that "whilst radiation treatment is proven to be a safe and highly effective cancer treatment, unwanted toxicities and side effects can occur due to changes in a patient's anatomy over the course of treatment. Optimising treatment post commencement, called 'adaptive radiotherapy', is labour intensive and complex. We're excited that through this collaboration with SeeTreat, we now have the opportunity to make adaptive radiotherapy more accessible for patients across our Australian network."

GenesisCare's decision to implement the SeeTreat ART.1 tool follows a multidisciplinary study of the software on 64 head and neck, breast, and prostate cancer patients treated on their mixed vendor linac platform assessing accuracy, efficiency and patient impact. The study showed significant potential benefits to standardising and scaling adaptive workflows, providing actionable insights to clinicians when they need it.

Radiation Oncologist, Dr Melanie Jackson, shares: "ART.1 is proving to be an easy-to-use tool to help me identify which of my patients would benefit from a new treatment plan and when this is optimal. The efficiency of the software and personalisation of care ensures we match our clinical team's effort and valuable resource time to achieve the best possible patient outcomes."

SeeTreat CEO and Founder, Dr Trang Nguyen said "GenesisCare is a truly patient-centric and innovative organisation with passionate doctors and clinical staff constantly striving to deliver the best care possible. Working with the GenesisCare team is a pleasure and we're proud to be collaborating with the group."

SeeTreat's ART.1 software has UKCA mark, CE mark, Australian ARTG registration and is FDA pending.

About SeeTreat

SeeTreat is doctor backed, physics led, software medical device company founded in 2023, led by Dr Trang Nguyen, Antonia Dalton and Professor Paul Keall. Our vision is to reduce the burden of cancer through broadly accessible software technology improving quality and accuracy of treatment. SeeTreat is a global company with a current install base in the UK, Europe, USA and Australia.

For more information visit https://www.seetreatmedical.com/ and follow SeeTreat on LinkedIn https://www.linkedin.com/company/seetreat-medical

About GenesisCare

GenesisCare is a proudly Australian-run cancer care provider, specialising in radiation therapy with a growing footprint in medical oncology, theranostics and personalised medicine. Our relentless pursuit for better care is reflected in our advanced treatment techniques, technology and contemporary service experience.

Our dedicated research team partners globally to be first movers in bringing clinical innovations to patients close to home.

Over 35,000 people a year entrust us with their care across more than 50 locations nationally.

Photo -

View original content:https://www.prnewswire.co.uk/news-releases/genesiscare-and-seetreat-to-bring-personalised-offline-adaptive-monitoring-to-more-than-40-radiation-oncology-centres-across-australia-302770327.html

Images

Tags

More Like This

Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT® in brain cancer patients

Together with Siemens Healthineers, Varian Showcases Commitment to Embracing Innovation and Enhancing Outcomes at ESTRO 2024

Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas®

GammaPod revolutionizes breast cancer treatment: Italy introduces high-dose stereotactic radiotherapy in a single session to Europe

Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT® in Brain Cancer

Curasight's uTREAT® Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

United Imaging Unveils Its Full Radiotherapy Portfolio at ESTRO 2026, Highlighting the CE-Marked uRT-linac 506c